<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019187</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 19108</org_study_id>
    <nct_id>NCT01019187</nct_id>
  </id_info>
  <brief_title>Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy</brief_title>
  <official_title>Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sleep disorder counseling may reduce fatigue and insomnia as well as improve the
      well-being and quality of life of cancer survivors. Armodafinil may help relieve insomnia and
      fatigue in patients with cancer after chemotherapy. PURPOSE: This randomized phase II trial
      is studying how well cognitive behavioral therapy with or without armodafinil works in
      treating cancer survivors with insomnia and fatigue after chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed DescriptionOBJECTIVES:

      I. To determine if one or more of the intervention strategies (i.e., CBT-I, armodafinil, or
      both), when compared to a placebo only group, reduce insomnia in cancer patients following
      the conclusion of chemotherapy and/or radiation therapy.

      II. To determine if one or more of the intervention strategies (i.e, CBT-I, armodafinil, or
      both), when compared to a placebo only group, reduce fatigue in cancer patients following the
      conclusion of chemotherapy and/or radiation therapy.

      III. To determine if one or more of the intervention strategies (i.e., CBT-I, armodafinil, or
      both), when compared to a placebo only group, improve QOL in cancer patients following the
      conclusion of chemotherapy and/or radiation therapy.

      OUTLINE: Patients are randomized to 1 of 4 treatment arms (cognitive behavioral therapy,
      armodafinil, both, or neither).

      After completion of study treatment, patients are followed for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of insomnia as assessed by the insomnia severity index and daily sleeep diaries.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue as assessed by the brief fatigue index</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Mid-point and end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue as assessed by the functional assessment of chronic illness therapy-fatigue</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep latency, wake after sleep onset, and total sleep time</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily for 47 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral armodafinil twice daily for 47 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fatigue Assessment and Management</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Fatigue Assessment/Management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleep Disorder Therapy</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Sleep disorders therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Quality of Life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fatigue Assessment and Management</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Fatigue Assessment and Mangement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Management of Therapy</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Complications of therapy management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleep disorder therapy</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality of Life assessment</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fatigue assessment and management</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Management of therapy and complications</intervention_name>
    <arm_group_label>Arm III</arm_group_label>
    <other_name>Compllications of therapy management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleep disorder therapy</intervention_name>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>sleep disorders therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality of Life Assessment</intervention_name>
    <description>Quality of Life Assessment</description>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Ancillary studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fatifue assessment and management</intervention_name>
    <arm_group_label>Arm IV</arm_group_label>
    <other_name>Fatigue Assessment/management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of cancer

          -  Be able to understand written and spoken English

          -  Be able to swallow medication

          -  Have preferred sleep phase between 7:30 pm and 11:00 am

          -  Be willing to discontinue any medications /OTCs/Herbals for sleep for the 11-week
             study period

          -  Be presumed to be in a state of cancer remission; use of tamoxifen, an aromatase
             inhibitor, and/or Herceptin is permitted

          -  Self-report problems with insomnia for at least three months and that the insomnia
             began or got worse with the onset of cancer or treatment

          -  At least one month must have passed since completion of chemotherapy and/or radiation
             treatment

          -  Report insomnia on the SDS-CL at a frequency of at least 3 days a week

        Exclusion Criteria:

          -  Have ever taken modafinil or armodafinil had CBT-I therapy (CBT-I therapy for the sake
             of this protocol will be defined as any cognitive behavioral-based treatment for
             insomnia that includes a sleep restriction component)

          -  Have an unstable medical or psychiatric illness (Axis I- current or within the last 5
             years)

          -  Have a history of seizures or severe headaches, or uncontrolled cardiac disease or
             hypertension

          -  Be presently taking an anticoagulant or a corticosteroid

          -  Have taken amphetamines (e.g., methylphenidate, pemoline [Cylert] or similar psycho
             stimulants) within the past 30 days

          -  Be currently pregnant or nursing

          -  Have a history of substance abuse, or meet criteria for current alcohol abuse or
             dependence as assessed by a CAGE test score &gt;= 2 or an Alcohol Use Disorders
             Identification Test (AUDIT) score &gt;= 13

          -  Have surgery planned within the study period

          -  Have ever been diagnosed with sleep apnea or have sleep apnea as indicated by
             endorsing either question 11 (I wake up choking or gasping for air) or question 12 (My
             bed partner has noticed that I seem to stop breathing) on the Sleep Disorders Symptom
             Check at the &quot;Often&quot; or &quot;Frequently&quot; level

          -  Have serious RLS/PLMs indicated by endorsing two or more items associated with
             RLS/PLMs on the Sleep Disorders Symptom Check at the &quot;Frequently&quot; level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Perlis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2009</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

